Search results for "Screen"

showing 10 items of 1374 documents

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

2018

We read with interest the article by Passamonti et al ,1 reporting the performance of two different faecal immunochemical tests (FITs) highlighting the importance of standardisation and validation of screening methodologies. Conventionally, laboratory-based FIT is the preferred approach in testing for occult blood in faeces, which includes colorectal cancer screening programmes.2–4 The potential of preserving stable faecal samples in a widely used FIT buffer for microbiome research would enable prospective microbiome studies in generally healthy subjects undergoing colorectal cancer screening. For this purpose, we evaluated faecal sample stability in the commonly used OC-Sensor (Eiken Chemi…

0301 basic medicineVeterinary medicine2312BiologySampling device03 medical and health sciencesHemoglobins0302 clinical medicineHumansMass Screening1506Microbiomecolonic microfloraEarly Detection of CancerMicrobiotaGastroenterologyHealthy subjectsIllumina miseqIon semiconductor sequencingPostScriptSample stabilityGastrointestinal Microbiome030104 developmental biologyColorectal cancer screeningMetagenomicsOccult Bloodepidemiology030211 gastroenterology & hepatologyGuaiacColorectal NeoplasmsGut
researchProduct

Repurposing old drugs to fight multidrug resistant cancers.

2020

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approa…

0301 basic medicineVirtual screeningCancer ResearchDrug repurposingSettore BIO/11 - Biologia MolecolareAntineoplastic AgentsDrug resistanceBioinformatics03 medical and health sciencesClinical cancer trials; Drug repurposing; Multidrug resistant cancer; Pharmacophore modelling; Virtual screening0302 clinical medicineNeoplasmsDrug DiscoveryMedicineHumansPharmacology (medical)Computer SimulationRepurposingPharmacologyVirtual screeningDrug discoverybusiness.industryDrug RepositioningComputational BiologyDrug Resistance Multiple3. Good healthMultiple drug resistanceDrug repositioning030104 developmental biologyInfectious DiseasesOncologyDrug developmentDrug Resistance Neoplasm030220 oncology & carcinogenesisMultidrug resistant cancerPharmacophore modellingPharmacophorebusinessClinical cancer trialsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

mD3DOCKxb: An Ultra-Scalable CPU-MIC Coordinated Virtual Screening Framework

2017

Molecular docking is an important method in computational drug discovery. In large-scale virtual screening, millions of small drug-like molecules (chemical compounds) are compared against a designated target protein (receptor). Depending on the utilized docking algorithm for screening, this can take several weeks on conventional HPC systems. However, for certain applications including large-scale screening tasks for newly emerging infectious diseases such high runtimes can be highly prohibitive. In this paper, we investigate how the massively parallel neo-heterogeneous architecture of Tianhe-2 Supercomputer consisting of thousands of nodes comprising CPUs and MIC coprocessors that can effic…

0301 basic medicineVirtual screeningMulti-core processorCoprocessorComputer sciencebusiness.industryParallel computingSupercomputer03 medical and health sciences030104 developmental biologyEmbedded systemScalabilityTianhe-2Algorithm designbusinessMassively parallel2017 17th IEEE/ACM International Symposium on Cluster, Cloud and Grid Computing (CCGRID)
researchProduct

2019

Golgi α-mannosidase II (GMII) is a glycoside hydrolase playing a crucial role in the N-glycosylation pathway. In various tumour cell lines, the distribution of N-linked sugars on the cell surface is modified and correlates with the progression of tumour metastasis. GMII therefore is a possible molecular target for anticancer agents. Here, we describe the identification of a non-competitive GMII inhibitor using computer-aided drug design methods including identification of a possible allosteric binding site, pharmacophore search and virtual screening.

0301 basic medicineVirtual screeningMultidisciplinaryChemistryCellAllosteric regulationGolgi apparatus010402 general chemistry01 natural sciencesEnzyme structure0104 chemical sciences03 medical and health sciencessymbols.namesake030104 developmental biologymedicine.anatomical_structureBiochemistrymedicinesymbolsGlycoside hydrolaseBinding sitePharmacophorePLOS ONE
researchProduct

Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders

2020

Contains fulltext : 218274.pdf (Publisher’s version ) (Closed access) Genetic syndromes frequently present with overlapping clinical features and inconclusive or ambiguous genetic findings which can confound accurate diagnosis and clinical management. An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called "episignatures"). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging pa…

0301 basic medicine[SDV]Life Sciences [q-bio]Computational biology030105 genetics & heredityBiologyPediatricsArticleCohort Studiesmolecular diagnostics03 medical and health sciencessymbols.namesakeGenetic HeterogeneityGene duplicationGeneticsHumansHunter-McAlpine syndromeGenetics (clinical)Mass screening030304 developmental biologyEpiSignGenetics0303 health sciencesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]DNA methylationGenetic heterogeneity030305 genetics & heredityCorrectionSyndromeDNA MethylationMolecular diagnosticsPhenotypePenetranceHuman genetics3. Good healthepisignaturegenomic DNA030104 developmental biologyPhenotypeNeurodevelopmental DisordersDNA methylationuncertain clinical casesMendelian inheritancesymbolsIdentification (biology)VUS classification
researchProduct

Effects of Pimozide Derivatives on pSTAT5 in K562 Cells

2017

STAT5 is a transcription factor, a member of the STAT family of signaling proteins. STAT5 is involved in many types of cancer, including chronic myelogenous leukemia (CML), in which this protein is found constitutively activated as a consequence of BCR-ABL expression. The neuroleptic drug pimozide was recently reported to act as an inhibitor of STAT5 phosphorylation and is capable of inducing apoptosis in CML cells in vitro. Our research group has synthesized simple derivatives of pimozide with cytotoxic activity and that are able to decrease the levels of phosphorylated STAT5. In this work we continued the search for novel STAT5 inhibitors, synthesizing compounds in which the benzoimidazol…

0301 basic medicineantiproliferationApoptosisPharmacologyBiochemistryAntineoplastic Agent0302 clinical medicinePimozidehemic and lymphatic diseasesDrug DiscoverySTAT5 Transcription FactorCytotoxic T cellPhosphorylationGeneral Pharmacology Toxicology and PharmaceuticsBCR-ABL-expressing leukemia; STAT5 inhibitors; antiproliferation; apoptosis; pimozideSTAT5Molecular StructurebiologyPimozidefood and beverages030220 oncology & carcinogenesisMolecular MedicinePhosphorylationHumanmedicine.drugAntineoplastic AgentsNOStructure-Activity Relationship03 medical and health sciencesK562 CellmedicineHumansTranscription factorCell ProliferationPharmacologyDose-Response Relationship DrugCell growthSTAT5 inhibitorsOrganic ChemistryApoptosiSTAT5 inhibitormedicine.disease030104 developmental biologyPharmacology Toxicology and Pharmaceutics (all)biology.proteinCancer researchBCR-ABL-expressing leukemiaDrug Screening Assays AntitumorK562 CellsK562 cellsChronic myelogenous leukemiaChemMedChem
researchProduct

Novel Modulators of Proteostasis: RNAi Screen of Chromosome I in a Heat Stress Paradigm in C. elegans

2018

Proteostasis is of vital importance for cellular function and it is challenged upon exposure to acute or chronic insults during neurodegeneration and aging. The proteostasis network is relevant for the maintenance of proteome integrity and mainly comprises molecular chaperones and two degradation pathways, namely, autophagy and the ubiquitin proteasome system. This network is characterized by an impressive functional interrelation and complexity, and occasionally novel factors are discovered that modulate proteostasis. Here, we present an RNAi screen in C. elegans, which aimed to identify modulators of proteostasis in a heat stress paradigm. The screen comprised genes that are located on ch…

0301 basic medicineautophagyproteostasis networkUPSArticle03 medical and health sciences0302 clinical medicinemedicinechaperonelcsh:QH301-705.5GeneRNAi screenGene knockdownproteostasisbiologyAutophagyNeurodegenerationneurodegenerationGeneral Medicinemedicine.diseaseCell biology030104 developmental biologyProteostasislcsh:Biology (General)ProteasomeChaperone (protein)Proteomebiology.proteinC. elegans<i>C. elegans</i>; RNAi screen; proteostasis; proteostasis network; autophagy; UPS; chaperone; neurodegeneration030217 neurology & neurosurgeryCells
researchProduct

2018

AbstractThe cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic screens in molecularly diverse breast tumor cell lines established that the E-cadherin/ROS1 synthetic lethality was not only robust in the face of considerable molecular heterogeneity but was also elicited with clinical ROS1 inhibitors, including foretinib and crizotinib. ROS1 inhibitor…

0301 basic medicinebiologyCrizotinibbusiness.industryForetinibSynthetic lethalitymedicine.diseaseCDH103 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineBreast cancerOncologychemistry030220 oncology & carcinogenesisbiology.proteinCancer researchROS1MedicinebusinessTyrosine kinaseGenetic screenmedicine.drugCancer Discovery
researchProduct

Quantitative Assessment of Eye Phenotypes for Functional Genetic Studies Using Drosophila melanogaster

2016

AbstractAbout two-thirds of the vital genes in the Drosophila genome are involved in eye development, making the fly eye an excellent genetic system to study cellular function and development, neurodevelopment/degeneration, and complex diseases such as cancer and diabetes. We developed a novel computational method, implemented as Flynotyper software (http://flynotyper.sourceforge.net), to quantitatively assess the morphological defects in the Drosophila eye resulting from genetic alterations affecting basic cellular and developmental processes. Flynotyper utilizes a series of image processing operations to automatically detect the fly eye and the individual ommatidium, and calculates a phen…

0301 basic medicinegenetic structuresNeurogenesisComputational biologyInvestigationsQH426-470EyeAnimals Genetically Modified03 medical and health sciences0302 clinical medicineOmmatidiumGeneticsAnimalsDrosophila Proteinshuman disease modelsEnhancerMolecular BiologyGeneGenetics (clinical)Genetic Association StudiesGeneticsGene knockdownbiologyModels Geneticneurodevelopmental disordersReproducibility of Resultsbiology.organism_classificationommatidiaPhenotypeeye diseases030104 developmental biologyPhenotypeDrosophila melanogastermodifier screensrough eyeGene Knockdown TechniquesEye developmentsense organsDrosophila melanogaster030217 neurology & neurosurgeryDrosophila ProteinFunction (biology)AlgorithmsG3: Genes, Genomes, Genetics
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct